Meeting
2015 ASCO Annual Meeting
A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN).
Authors
Qinyang Li
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
Qinyang Li , Jian Guan , Yue Zhang , Min Chen , Lu Li , Nanjie Xiao , Mi Yang , Yongmei Dai , Chi Zhang , Longhua Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 6036)
DOI
10.1200/jco.2015.33.15_suppl.6036
Abstract #
6036
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A Big Ten Cancer Research Consortium phase II trial of pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer.
First Author: Mario Javier Pineda
Poster
2011 ASCO Annual Meeting
COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC).
First Author: A. Rossi
Poster
2023 ASCO Annual Meeting
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.
First Author: Thiago Bueno Oliveira Sr.
Poster
2021 ASCO Annual Meeting
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
First Author: Amit M. Oza